AlzeCure
Issue outcome signals recovery for biotech
After years of difficulty accessing capital, the Swedish biotech sector is showing signs of recovery....
Bioteknik
Emission
Premium
Cecilia Wadell new Head of Development at AlzeCure
AlzeCure presents ACD440 at NeuPSIG 2025
AlzeCure's ACD440 granted orphan drug status by the FDA
Rights issue strengthens AlzeCure's position
AlzeCure Pharma is conducting a rights issue of SEK 48,5 million,...
Emission
Five Nordic biotech stock market winners in H1 2025
Vacation times are approaching and when 2025 is now...
Premium
AlzeCure's CEO: "Increased interest after EIC grant and FDA feedback"
Today marks the start of the subscription period for AlzeCure Pharma's rights issue,...
Emission
Intervju
News roundup Thursday, June 5
News roundup Thursday, February 27
Alligator Bioscience
News roundup Tuesday, February 18
AlzeCure
News roundup Tuesday, January 21
Elicera Therapeutics
The news sweep Wednesday 30 October
From Seed to Success 2024